Get started
Author

Arshad Mujeebuddin

Observed name: A. Mujeebuddin
ORCID: 0000-0002-4752-7016
Observed ORCID: 0000-0002-4752-7016
OpenAlex ID: A5001900852
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
2019 · Gérard Socié, Marie‐Pierre Caby‐Tosi, et al. · British Journal of Haematology · 249
PDF
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies
2022 · Austin G. Kulasekararaj, Morag Griffin, et al. · European Journal Of Haematology · 76
PDF
First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals
2015 · Leonardo Sahelijo, Arshad Mujeebuddin, et al. · Blood · 28
Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications
2025 · Cynthia Carrillo Infante, Arshad Mujeebuddin · PLoS ONE · 18
PDF
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement
2023 · Rohtesh S. Mehta, Haris Ali, et al. · Bone Marrow Transplantation · 10
PDF
Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients
2023 · Sami Fam, Brian Werneburg, et al. · Journal of the Neurological Sciences · 6
PDF
P812: Long-term Complement Inhibition and Survival Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: an Interim Analysis of the Ravulizumab Clinical Trials
2022 · A. Kulasekararaj, R. Brodsky, et al. · HemaSphere · 4
Safety of ravulizumab use in pregnancy: Insights from a global pharmacovigilance analysis
2025 · Heather Sherrard, Cynthia Infante, et al. · Blood · 2
PDF
Incidence and Outcome of Meningococcal Infection With Eculizumab or Ravulizumab in Patients With gMG or NMOSD: An Analysis of US Clinical Practice
2024 · Shirali Pandya, Lokesh Jha, et al. · Neurology · 2
Characterization of Antibiotic Prophylaxis Risk Mitigation Practices Across Eculizumab and Ravulizumab Adult, Phase III Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder
2026 · Ukwen Akpoji, Shirali Pandya, et al. · Neurology
PDF
Safety of Ravulizumab Use in Pregnancy: Insights from a Global Pharmacovigilance Analysis
2026 · Cynthia Carrillo Infante, Arshad Mujeebuddin, et al. · Advances in Therapy
PDF
Pregnancy Outcomes Following Ravulizumab Exposure: A Pharmacovigilance Analysis
2025 · Cynthia Carrillo Infante, Heather Sherrard, et al. · Journal of the American Society of Nephrology
Safety Findings in Patients With Anti-Aquaporin-4-Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Who Received Eculizumab or Ravulizumab in the PREVENT and CHAMPION-NMOSD Studies and Had Received Rituximab Within 1 Year Prior to Enrollment
2024 · Michael Levy, Becky Parks, et al. · Neurology
Ravulizumab is a Suitable Long-Term Treatment Option for Patients with Paroxysmal Nocturnal Hemoglobinuria
2023 · Austin G. Kulasekararaj, Morag Griffin, et al. · Future Rare Diseases
PDF
Works count: 15
Citation count: 395
H-index: 6
I10-index: 5
Year
Topic
Type